Back to companies

Kodiak Sciences Inc (Kodiak Sciences) is a drug development company. The company is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high prevalence ophthalmic diseases. Its pipeline products portfolio includes KSI 301 an anti-VEGF biologic development, which offers wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy; KSI-501 an anti-IL6 and anti-VEGF bispecific biopolymer conjugate; and KSI-601 a triplet biopolymer conjugate, which treats dry age-related macular degeneration. Kodiak Sciences utilizes proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, that combines biologics design with next generation phosphorylcholine biopolymers. It commercializes technology to both bio-pharmaceuticals and small molecules companies. The company operates in the US and Switzerland. Kodiak Sciences is headquartered in Palo Alto, California, the US.

Headquarters United States of America

Address 1200 Page Mill Rd, Palo Alto, California, 94304

Website kodiak.com

Telephone 1 650 2810850

No of Employees 101

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange KOD (NASD)

EPS XXX

Net Income (2020) XXX -100.6% (2020 vs 2019)

Market Cap* $395.5M

   

   

* As of and is in US$

Access premium data and analytics for Kodiak Sciences Inc

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Kodiak Sciences Inc’s relevant decision makers and contact details.

9

Clinical Trials

Determine Kodiak Sciences Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

7

Pipeline Drugs

Identify which of Kodiak Sciences Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services
Pipeline Product: Research Services
KSI 301: Retinal Vascular Disease
KSI-501: Retinal Vascular Disease
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In August, the company completed enrollment in its GLOW Phase 3 clinical trial of tarcocimab tedromer, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with Non-Proliferative Diabetic Retinopathy without diabetic macular edema.
2022 Corporate Changes/Expansions In May, the company and Lonza Group opened a new bioconjugation facility in Visp, Switzerland.
2022 Official Trials/Tests In February, the company announced results from its initial Phase 2b/3 study of KSI-301 in patients with neovascular (Wet) age-related macular degeneration.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Kodiak Sciences Inc F. Hoffmann-La Roche Ltd Novartis AG Flexion Therapeutics Inc Apoplogic Pharmaceuticals Inc
Headquarters United States of America Switzerland Switzerland United States of America United States of America
City Palo Alto Basel Basel Burlington Aurora
State/Province California - - Massachusetts Colorado
No. of Employees 101 100,920 108,000 257 -
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Victor Perlroth, MD Chairman; President; Chief Executive Officer Executive Board 2009 48
John Borgeson Secretary; Chief Financial Officer; Senior Vice President Senior Management 2016 59
Jason S. Ehrlich, M.D., Ph.D. Chief Medical Officer; Chief Development Officer Senior Management 2018 45
Sinette Heys Vice President - Clinical Operations Senior Management - -
Laurent Ducry Vice President - Biologics Development and Manufacturing Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer